Andy Merritt
Dr Andy Merritt has held the post of Head of Chemistry at the LifeArc (formerly MRC Technology) Centre for Therapeutics Discovery (CTD) since the summer of 2009. In close collaboration with academic scientists, the CTD develops and subsequently prosecutes innovative drug discovery programmes emerging from academic research, in oncology, neuroscience and diseases of the developing world. Prior to his current position, Andy was a Director of Discovery Medicinal Chemistry at GlaxoSmithKline. Andy joined the former Glaxo organization as a senior medicinal chemist in 1988 following postdoctoral studies in the US. Andy sat on the RSC Chemistry World editorial board between 2003 and 2019, has been a regular undergraduate lecturer in pharmaceutical medicine at Imperial College, Warwick and Sussex universities, and was the industrial organiser for the RSC Medicinal Chemistry residential summer school between 1999 and 2005.
AstraZeneca
AstraZeneca is a global, innovation and research-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, renal, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.